Compare Ginkgo Bioworks Holdings Inc (DNA) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs TKO Group Holdings Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M), while TKO Group Holdings Inc trades at $184.56 (market cap $13.84B). The key difference: TKO Group Holdings Inc is far larger — about 23.4× Ginkgo Bioworks Holdings Inc's market cap, and TKO Group Holdings Inc pays a 1.69% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | TKO | |
|---|---|---|
Market Cap | $590.53M | $13.84B |
Sector | Health | Technology |
52-Week High | $16.14 | $224.96 |
52-Week Low | $5.48 | $155.61 |
Enterprise Value | $627.78M | $18.01B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
TKO Group Holdings trades at $180.96, down 1.87% on the day, with mixed technical signals showing bearish moving averages but bullish oscillators. The company reported strong Q1 2026 earnings beat but missed Q3 and Q4 2025 expectations. Revenue grew to $4.74B in 2025 with net income of $195.4M, while 2026 projections show continued growth to $5.1B revenue. Recent developments include successful international events and an $800M share repurchase completion.
Wall Street maintains strong bullish sentiment with 89% buy ratings and $228 consensus price target, representing 26% upside. Key risks include execution on earnings guidance and competitive pressures in sports entertainment. The company's premium valuation (P/E 68.6) requires sustained growth delivery, while positive cash flow trends and dividend payments provide shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
